Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-08
  • 2025-07
  • 2025-06
  • AZD0156: ATM Kinase Inhibitor Workflows for DNA Repair Resea

    2026-07-29

    AZD0156: Transforming ATM Kinase Inhibition in DNA Damage Response Research

    Principle Overview: Targeting ATM Kinase for DNA Repair and Cancer Studies

    ATM kinase is a master regulator of the DNA damage response, orchestrating the detection and repair of double-strand breaks (DSBs), checkpoint control, and genomic stability. Inhibiting ATM kinase has emerged as a powerful strategy to sensitize tumor cells to DNA-damaging agents and to dissect checkpoint control mechanisms in preclinical models. AZD0156 stands out as a highly potent and selective ATM kinase inhibitor, achieving sub-nanomolar inhibition and demonstrating >1000-fold selectivity over other PIKK family members. This selectivity is critical for minimizing off-target effects and for confidently attributing observed cellular phenotypes to ATM inhibition.

    Developed with rigorous purity standards (≥98% by HPLC/NMR) and validated in diverse preclinical cancer models, AZD0156 is currently a cornerstone in both mechanistic studies and translational research targeting DNA repair pathways and checkpoint modulation. Its oral bioavailability and robust performance in potentiating antitumor responses to genotoxic agents further underscore its utility in cancer therapy research and combination strategy development.

    Step-by-Step Experimental Workflows and Protocol Enhancements

    Incorporating AZD0156 into DNA damage response experiments unlocks new dimensions of control and sensitivity. Below is a streamlined workflow for leveraging AZD0156 in cell-based DNA double-strand break repair assays, with emphasis on maximizing reproducibility and signal specificity.

    Protocol Parameters

    • Compound solubilization: Dissolve AZD0156 at 23.1 mg/mL in DMSO with gentle warming to 37°C, ensuring complete dissolution before dilution into experimental media.
    • Working concentration: Treat cells with 100 nM AZD0156 for 1–24 hours, based on endpoint requirements (e.g., checkpoint activation or DNA repair readouts), as supported by preclinical protocols (related resource).
    • Combination with DNA-damaging agents: Pre-treat cells with AZD0156 for 2 hours prior to addition of agents such as doxorubicin (1 μM) or ionizing radiation (2–10 Gy), then monitor DNA repair kinetics over 24 hours (complementary workflow).

    For high-content imaging or flow cytometry, fixation and staining for γ-H2AX, 53BP1, or checkpoint markers (e.g., p-Chk2) are typically performed 4–6 hours post-treatment. Always include vehicle controls and, if possible, a positive control for ATM inhibition to benchmark assay sensitivity.

    Advanced Applications and Comparative Advantages

    AZD0156's exquisite selectivity and bioavailability open multiple advanced avenues for research:

    • Combination Therapies: AZD0156 is an ideal candidate for synergy studies with DNA-damaging chemotherapeutics, PARP inhibitors, or metabolic modulators. Recent work shows that ATM inhibition can synergize with fenofibrate to induce senescence in high-grade serous ovarian cancer cells, revealing new vulnerabilities beyond homologous recombination deficiency (extension of application).
    • Checkpoint Control Modulation: By selectively blocking ATM, researchers can dissect the roles of G1/S and G2/M checkpoints in response to DSBs, enabling fine mapping of DNA repair pathway choice and checkpoint fidelity.
    • In Vivo and Translational Research: Oral bioavailability allows for straightforward translation from in vitro to animal models, facilitating pharmacodynamic and efficacy studies in tumor xenografts or patient-derived organoids.
    • Genomic Stability Investigations: AZD0156’s high specificity is particularly advantageous in studies where off-target inhibition of other PIKKs (such as ATR or DNA-PKcs) would confound results—a point repeatedly validated in comparative studies (complementary resource).

    Key Innovation from the Reference Study

    The referenced systematic analysis of AKT inhibitors provides a paradigm for evaluating kinase inhibitors not just by potency, but by class-specific molecular signatures and functional phenotypes. The study illustrates how ATP-competitive and allosteric inhibitors can yield divergent biological outcomes due to their distinct binding modes and isoform selectivity. Translating this insight to ATM kinase inhibitor workflows, it is critical to:

    • Profile phosphoproteomic signatures following AZD0156 treatment to confirm on-target ATM pathway inhibition and to distinguish from effects mediated by ATR or DNA-PKcs interference.
    • Benchmark cellular phenotypes (e.g., apoptosis, senescence, checkpoint abrogation) in the context of both wild-type and mutant background lines, mirroring the reference study’s approach to isoform-specific responses and resistance mechanisms.
    • Use AZD0156 as a chemical probe in combination screens to identify synthetic lethality or resistance bypass, as the reference study did for AKT inhibitor combinations.

    This strategy ensures that research with AZD0156 is both mechanistically informative and translationally relevant.

    Troubleshooting and Optimization Tips

    • Solubility and Precipitation: AZD0156 is insoluble in water; always dissolve in DMSO or ethanol as per product specifications. For cell culture, keep final DMSO concentration below 0.1% to minimize cytotoxicity.
    • Compound Stability: Prepare fresh AZD0156 solutions before each experiment. Although stable at -20°C as a solid, avoid long-term storage once dissolved, as potency may decrease (see product details).
    • Assay Sensitivity: Validate ATM inhibition by monitoring downstream phosphorylation events (e.g., p-Chk2 at Thr68 or γ-H2AX foci formation). If signal is weak, verify compound integrity and titrate dose between 50–200 nM.
    • Off-target Effects: While AZD0156 is highly selective, verify that observed phenotypes are ATM-dependent by including genetic knockout or siRNA controls where possible.

    For troubleshooting persistent variability, consult both the evidence-based workflow resource and APExBIO’s technical support for batch-specific guidance.

    Interlinking Evidence: Complementary and Extension Resources

    Future Outlook: Implications for Cancer Therapy Research

    AZD0156 is rapidly consolidating its position as the ATM kinase inhibitor of choice for researchers aiming to unravel the complexities of DNA damage response and checkpoint control. The rigorous, multi-modal characterization of kinase inhibitors—exemplified by the AKT inhibitor reference study—underscores the importance of integrating molecular profiling, functional readouts, and combination assays in preclinical evaluation. As early-phase clinical trials continue to assess AZD0156’s safety and efficacy, the insights gained from bench research will be pivotal in guiding rational combination strategies and understanding mechanisms of resistance or synthetic lethality.

    Researchers using AZD0156 supplied by APExBIO can have confidence in both compound quality and the expanding knowledge base supporting its optimal use. Continued cross-validation with emerging DNA repair inhibitors and checkpoint modulators will further clarify its best-fit applications and therapeutic windows. Ultimately, the methodical, evidence-driven use of AZD0156 is set to accelerate discoveries in cancer therapy research and precision medicine.